{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:33:45Z","timestamp":1787762025356,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Narrowband ultraviolet B (NBUVB) phototherapy is an established treatment for vitiligo. However, real-world practices vary significantly, particularly in dosing strategies, maintenance schedules, and the use of minimal erythema dose (MED) testing, impacting treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim and Objectives:<\/jats:title>\n                    <jats:p>To assess NBUVB phototherapy practices among Indian dermatologists, evaluate patient characteristics and treatment outcomes, and identify variations in clinical protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>An online, questionnaire-based survey was conducted among 80 Indian dermatologists who responded actively using NBUVB. The questionnaire was validated through expert review, pilot testing, and reliability assessment before deployment. Validation included content validation by three senior dermatologists with more than 15 years of phototherapy experience to ensure item relevance and clarity. A pilot test among 10 dermatologists confirmed internal consistency. Data were analyzed using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 80 respondents (response rate of 5%), 65% had &gt;10 years\u2019 experience. Most respondents (52.5%) used only NBUVB whole-body units, while others employed combination or targeted phototherapy devices. MED testing was performed by only 30%, typically using visual test dose methods; 70% used empirical starting doses. A 200 mJ\/cm\u00b2 starting dose was most common (60%). Maintenance therapy was administered every 1\u20132 weeks in 75%. Early clinical improvement was observed after 10\u201320 sessions, and &gt;50% re-pigmentation in vitiligo occurred after 50\u201370 sessions in 85%. Acral vitiligo showed a mixed response, with poor or limited response in 60% of cases. Mild erythema (80%) and burning (60%) were the most reported side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>The study is limited by self-reported data, possible recall bias, and lack of detail on MED testing procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is marked variability in NBUVB protocols among Indian dermatologists. Emphasizing standardized guidelines and MED-based personalized dosing could improve therapeutic outcomes and patient safety in vitiligo management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_80_25","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:03:38Z","timestamp":1781078618000},"page":"539-543","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Narrowband Ultraviolet B Phototherapy Practices among Indian Dermatologists for Vitiligo"],"prefix":"10.4103","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-5343","authenticated-orcid":false,"given":"Senkadhir","family":"Vendhan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Southern Railways Headquarters Hospital, Perambur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataram","family":"Mysore","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venkat Charmalaya - Centre for Advanced Dermatology, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"R1-20260629","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3390\/medicina59101753","article-title":"common skin diseases and their psychosocial impact among Jazan population, Saudi Arabia: A Cross-sectional survey during 2023","volume":"59","author":"Mahfouz","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R2-20260629","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4103\/idoj.IDOJ_310_18","article-title":"What is new in narrow-band ultraviolet-B therapy for vitiligo?","volume":"10","author":"Khanna","year":"2019","journal-title":"Indian Dermatol Online J"},{"key":"R3-20260629","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/0378-6323.48662","article-title":"Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo","volume":"75","author":"Kishan Kumar","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R4-20260629","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fmed.2018.00184","article-title":"A Perspective on the use of NB-UVB phototherapy vs PUVA photochemotherapy","volume":"5","author":"Ibbotson","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R5-20260629","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/0019-5154.113944","article-title":"Phototherapy in vitiligo: Assessing the compliance, response and patient's perception about disease and treatment","volume":"58","author":"Kandaswamy","year":"2013","journal-title":"Indian J Dermatol"},{"key":"R6-20260629","first-page":"e50175","article-title":"Minimal erythema dose testing","volume":"75","author":"Heckman","year":"2013","journal-title":"J Vis Exp"},{"key":"R7-20260629","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, from physiopathology to emerging treatments: A review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R8-20260629","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bjd.21669","article-title":"British association of dermatologists'clinical standards unit. British association of dermatologists and british photodermatology group guidelines for narrowband ultraviolet B phototherapy 2022","volume":"187","author":"Goulden","year":"2022","journal-title":"Br J Dermatol"},{"key":"R9-20260629","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","article-title":"The vitiligo working group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo","volume":"76","author":"Mohammad","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R10-20260629","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1468-3083.2011.04215.x","article-title":"Acral lesions of vitiligo: Why are they resistant to photochemotherapy?","volume":"26","author":"Esmat","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20260629","doi-asserted-by":"crossref","first-page":"00089","DOI":"10.2340\/00015555-3453","article-title":"Adverse events leading to discontinuation of phototherapy: An observational study","volume":"100","author":"Belinch\u00f3n","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R12-20260629","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/abd1806-4841.20142717","article-title":"Vitiligo\u2013Part 2-classification, histopathology and treatment","volume":"89","author":"Faria","year":"2014","journal-title":"An Bras Dermatol"},{"key":"R13-20260629","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s12325-024-02875-0","article-title":"Epidemiology and treatment patterns of patients with vitiligo: A real-world analysis","volume":"41","author":"Ramot","year":"2024","journal-title":"Adv Ther"},{"key":"R14-20260629","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/etm.2021.10229","article-title":"Updates and new medical treatments for vitiligo (Review)","volume":"22","author":"Kubelis-L\u00f3pez","year":"2021","journal-title":"Exp Ther Med"},{"key":"R15-20260629","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3390\/jcm12051984","article-title":"Management of stable vitiligo-A review of the surgical approach","volume":"12","author":"Grochocka","year":"2023","journal-title":"J Clin Med"},{"key":"R16-20260629","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0378-6323.90950","article-title":"Survey of dermatologists'phototherapy practices for vitiligo","volume":"78","author":"Alghamdi","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_80_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:12:11Z","timestamp":1787760731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_80_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_80_25","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"2025-01-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}